Recursion Pharmaceuticals (RXRX) investor relations material

Platform integration and AI strategy

• Integrates biology, chemistry, and ClinTech pillars to predict and address failure points in drug discovery and development.

• AI-native approach enables faster, cheaper solutions without legacy infrastructure, focusing on data-driven decision-making.

• Partnerships with Roche, Sanofi, and NVIDIA have brought in over $500 million and support a diversified, profitable business model.

• ClinTech business, built from scratch, leverages real-world data to accelerate clinical trials by 30%-60%.

• Continuous impact modeling and cost efficiency measures have reduced budgets by 35% post-merger.

Pipeline and clinical development

• Five clinical programs are active, with key data readouts expected over the next 12-18 months.

• Lead program 4881 targets FAP, with FDA discussions ongoing and major updates on trial design and broader patient data expected soon.

• RBM39 program shows promising safety and PK/PD data, with more results anticipated later this year.

• MALT1 and CDK7 programs will have data readouts early next year; LSD1 program initiated for the second half of next year.

• Programs undergo rigorous multi-parameter analysis for scientific, clinical, and commercial viability.

Differentiation and business model

• Focus on risk diversification, balancing best-in-class and first-in-class assets, and maintaining a mix of wholly owned and out-licensed programs.

• Partnership business operates at breakeven or profit, with advance payments covering direct costs.

• Out-licensing is a future strategy to maximize option value and capital management.

• Impact-driven cost management ensures only high-impact spending remains, supporting a broad pipeline.